Therapeutic area
First-Line Study for Metastatic Non-Small Cell Lung Cancer
Back to studiesRecruiting
Therapeutic area
Oncology — Lung Cancer
General profile of the patient sought
Intended for people with stage IV non-small cell lung cancer, PD-L1 expression above 50%, and no prior systemic treatment for metastatic disease. Participants must have an ECOG performance status of 0–1, meaning they are fully active or have mild limitations with physically strenuous activities. Eligibility also depends on the tumor’s molecular characteristics and other medical criteria reviewed by the research team.
Principal investigator
Dr. Carlos Zuloaga
A clinical study comparing two immunotherapy options as initial treatment for people with metastatic non-small cell lung cancer and high PD-L1 expression. The study aims to evaluate the efficacy and safety of the treatments being studied.